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Psoriasis is a chronic inflammatory systemic disease characterized by a wide range of comorbidities. Respiratory comorbidities are
currently poorly characterized and with discordant results. The systemic state of inflammation caused by psoriasis acts de novo
on respiratory tissues and amplifies preexisting inflammation from asthma or chronic obstructive pulmonary disease. Because
the lungs act as a gas exchanger between the internal and external environment, the impact of chronic psoriasis inflammation
may be easily assessed through the analysis of exhaled breath. The fraction of exhaled nitric oxide test (FeNO) is a potential
noninvasive solution that can provide quantitative and qualitative indices of respiratory airway inflammation. FeNO is routinely
used to screen and manage asthmatic patients. Recent pilot studies contain encouraging data that underscore its possible use with
systemic inflammatory nonpulmonary diseases, such as psoriasis. FeNOmay therefore be a useful tool to evaluate underestimated
airway inflammation and at the same time globally evaluate the impact of systemically antipsoriatic therapies.
1. Introduction
Psoriasis (PS) is a chronic inflammatory systemic disease
[1–4], characterized by scaling and erythematous plaques. It
affects 2-3% of the present population [5]. From its relapsing
remitting behaviour to related comorbidities, many bodies
of evidence have proposed the idea that psoriasis extends
beyond the skin [6]. Literature has shown PS-systemic
inflammation is associated with higher risk of developing
depression [7], cardiovascular events [8], diabetes [9], and
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Table 1: Fractions of exhaled nitric oxide display increased levels in autoimmune and inflammatory systemic disease.
FRACTIONOF EXHALED NITRIC OXIDE (FENO) IN AUTOIMMUNE/INFLAMMATORY DISEASES
DISEASE FENO STUDIES
Psoriasis ↑ Malerba M, et al. [19]
Damiani G, et al. [20]
Malerba M, et al. [21]
Juvenile idiopathic arthritis ↑ Dog˘ruel D, et al. [31]
Systemic sclerosis ↑ Guillen-Del Castillo A, et al. [32]
Sarcoidosis ↑ Choi J, et al. [33]
Intestinal bowel disease (IBD) ↑ Furlano RI, et al. [34]
obstructive sleep apnea syndrome (OSAS) [10, 11]. Respira-
tory comorbidities are currently poorly characterized with
conflicting findings [12–14]. Difficulties in assessing lung
comorbidities in PS patients may be categorized into two
main groups: (1) low compliance of PS patients to be exten-
sively assessed [15]; (2) lack of a validated noninvasive,
inexpensive, convenient tool. Educating patients that pso-
riasis not only affects the skin but also targets joints [16],
entheses [17, 18], and the entire body by maintaining a
chronic inflammatory status can help resolve problems with
patient compliance. Creating a noninvasive assessment tool
for potential lung comorbidities is the main focus of this
review. Multiple epidemiological studies outline a possible
correlation between PS and respiratory diseases [12–14].They
highlight an increased risk of asthma, chronic obstructive
pulmonary disease (COPD), and airway infections in PS
patients [14]. These diseases share common inflammatory
pathogenic pathways with other psoriasis comorbidities [8].
Although the exact mechanism of PS comorbidities is still
unclear, the most accepted hypothesis is that proinflam-
matory cytokines spill over through the blood from active
psoriatic plaques, causing inflammation in distant tissues
[19–21]. Each tissue responds in a specific way to the insult,
such as atherosclerosis in the coronary and carotid vessel [22].
In addition, genetically predisposed individuals [23], whose
proinflammatory cytokines trigger long distance inflamma-
tion, may exhibit consolidation and auto-maintenance [24].
This pathogenic theory designated as the “psoriatic march”
was postulated by Boehncke. It attempts to explain the
epidemiological correlation of psoriasis and cardiovascular
comorbidities linked by a mechanism driven by systemic
inflammation [24].This idea could theoretically be applicable
to all PS comorbidities, including respiratory. In fact, recent
literature has described impaired lung function in psoriatic
patients exhibiting lower mean Force Expiratory Volume in
the 1𝑠𝑡 second (FEV1)/Force Vital Capacity (FVC) ratios and
Forced Expiratory Flow (FEF) 25-75% [25]. Biological data
confirms this theory, stating there is an increased tissue sensi-
tivity to several proinflammatory cytokines including tumour
necrosis factor-𝛼 (TNF𝛼) and interleukin-1 (IL-1)[26]. This
has been observed in psoriasis plaques and the blood of PS
patients [26]. These cytokines act locally, in an autocrine
or paracrine way, to maintain endocrine-like behaviour. If
present in high enough concentration cytokines may also
manifest endocrine-like behaviour, causing inflammation in
other body areas [27]. This includes the airways through
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF𝜅B) signaling transcription of several key enzymes, such
as the inducible form of nitric oxide synthase (iNOS) which
produces nitric oxide (NO) [28]. Because the lungs act as
a gas exchanger between the internal and external environ-
ment, the impact of chronic psoriasis inflammation may be
assessed by the analysis of fraction of exhaled nitric oxide
(FeNO). FeNO could provide a quantitative and qualitative
indicator of respiratory airway inflammation [29], as it is
routinely used to screen and manage asthmatic patients [30].
Pilot studies have highlighted the possible use of FeNO in
systemic inflammatory nonpulmonary diseases [Table 1] [31–
34], such as psoriasis. In this review, we describe the rationale
and possible applications of FeNO in the management of
PS.
2. Asthma and Psoriasis
Previous studies suggested a possible link between asthma
and psoriasis [12–14]. Furthermore, asthma may be con-
sidered an umbrella term that groups different patterns of
airway inflammation: paucigranulocytic (≤3% eosinophils,
<64% neutrophils) and eosinophilic (>3% eosinophils, <64%
neutrophils) without increased total cell counts, neutrophilic
(≤3% eosinophils, ≥64% neutrophils) and mixed granulo-
cytic (>3% eosinophils, ≥64% neutrophils) [63]. Although
Th2 cells have a well-defined role in eosinophilic inflam-
mation initiated by releasing IL-4, IL-5, and IL-13 and Th1
and Th17 cells may also lead to the neutrophilic response
by releasing IL-6, IL-12, IL-17, and IL-23[64]. IL-23 itself
has been suggested tomediate neutrophilic antigen-mediated
recruitment and at the same time eosinophilic recruitment
via Th2 in the airways [65]. The pathophysiology is also
enriched by several overlapping genetic risk loci that link pso-
riasis to asthma [66–68]. A recent meta-analysis described
that asthma risk in PS patients is higher and that patients
>50 years old have the highest risk [69], due to the increased
duration of long-term inflammation in the airways.
Nadeem et al. have recreated in a mouse model the coex-
istence of psoriasis and asthma by triggering psoriasis with
topical application of imiquimod and asthma by sensitizing
mice airways with cockroach extract [70]. Mice treated in
this manner had an increased count of both neutrophils
and eosinophils in the airways, suggesting that psoriasis may
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increase airway inflammatory pattern [70]. This hypothesis
was ultimately confirmed in these mice by the increased
number of both Th17 and Th2-specific cells as identified
by STAT3-RORC and GATA3 [70]. Interestingly a topical
inhibitor of STAT3 decreased both Th17 and Th2 counts,
suggesting that Th17 have a prominent role in triggering and
modulating inflammation in both the skin and the lung [70].
A unique case reports IL-12\IL-23 inhibitors as effective in
treating a patient affected by both psoriasis and asthma [71].
3. COPD and Psoriasis
The relationship between COPD and psoriasis is highlighted
by two distinct meta-analyses that suggest an association
between these two chronic inflammatory diseases [72, 73].
In particular Ungprasert et al. found that COPD in PS
patients has an odds ratio of 1.45 (95% CI, 1,21-1,73) by
evaluating a total of 7 studies and 331,347 patients [74–80].
Recently Wu and colleagues analysed 110,729 incidental cases
of psoriasis and their comorbidities, clustering the entire
sample in 4 classes; one which manifests a propensity to
develop COPD and hypertension [81]. Despite the nature
of immune system dysfunction in COPD remaining largely
unknown, the crosstalk between innate and adaptive immu-
nity has been shown previously to lead to increased severity
[82]. Dysfunctional neutrophils chemoattraction lead to a
premature diapedesis and neutrophilic elastase release that
inhibits dendritic cells (DCs) maturation, increased mucin
production, and decreased lung function [83]. The active
respiratory epithelium releases MIP3𝛼/CCL20 that informs
and recruits Th17 and DCs [84]. In fact, in COPD, as well as
in psoriasis, patients demonstrate an imbalance betweenTh17
and Treg, a finding confirmed by Wang and colleagues [84].
High levels of Th17 cells in small airway associate with poor
function; in particular, IL-17A and IL-17F trigger and lead
to development of neutrophilic airway inflammation [83].
This inflammatory pattern was also tested by Nadeem and
colleagues who found that psoriasis triggers and is triggered
by airway inflammation [70].
4. Exhaled Nitric Oxide (FeNO) Measurement
All NO synthase (NOS) isoenzymes convert L-arginine to
L-citrulline with the generation of NO [85]. Constitutive
NOS includes neuronal-NOS (NOS1 or nNOS), endothelial-
NOS (NOS3 or eNOS), and mitochondrial-NOS (mtNOS)
[86, 87]. Inducible-NOS (iNOS or NOS2) is expressed only in
response to inflammatory and infectious triggers, producing
large quantities of NO independently by calcium ion influx
[88]. NO in the lungs is mainly produced by the alveoli
epithelium andmoves to the lumen driven by a concentration
gradient. Consequently, FeNO is a flow-dependent measure
[89].The gold standard to assess FeNO is an inline method by
which expiration is continuously sampled by an NO analyser.
The resultant NO profile versus time or exhaled volume
together with other exhalation variables (airway flow rate
and/or pressure) is captured and displayed in real-time [89].
The patient inhales NO sampled air through a preassessed
calibrated mouthpiece up to total lung capacity and then
exhales without holding their breath, as a breath hold would
increase NO diffusion time from the airway wall to air and
cause inaccurate results. It is for this same reason that low
exhalation flow rates increase FeNO and high ones decrease
them. It is common practice to display the pressure or
expiratory flow rate to the subject, who is subsequently asked
to maintain a positive mouthpiece pressure between 5 and 20
cmH2O to avoid nasal backflow of NO. A nose clip should
also be avoided. Correct exhalation should last for>6 seconds
(exhaled volume of at least 0.3 L at 50 mL/s) resulting in
a single-breath NO profile (exhaled NO versus time plot)
that consists of a washout phase followed by a plateau of at
least 3 seconds. Repeated exhalations should be performed to
obtain at least 2 values that agree within 10% of each other.
Exhaled NO is then calculated as the mean of the two values.
At least 30 seconds of tidal breathing off the circuit should
elapse between exhalations [89]. FeNO obtained at 50 mL/s
is a reliable source of the production of NO in respiratory
airways, but there is no simple surrogate for determining
the distal airway/alveolar concentration of NO (CANO),
because FeNO must be obtained at multiple expiratory flow
rates in order to be able to distinguish between the airway
production and CANO: 30, 50, 100, and 200 mL/s [89].
Physiological and pathological conditions responsible for
affecting FeNOmeasurements are reviewed and summarized
in Table 2 [35–62]. According to the AmericanThoracic Soci-
ety (ATS)/European Respiratory Society (ERS) guidelines,
nondisease related patient factors influencing FeNO values
are very young age (children), female sex (during menses or
pregnancy), respiratory maneuvers (performing spirometry
reduces FeNO), airway calibrating, some food and beverages,
smoking (which reduces FeNO chronically and acutely),
infections, hypoxia, exercise, andmedications directly related
to NO synthesis [89] (Table 2).
5. Nitric Oxide as a Mediator of
Inflammatory Disease
Initial pulmonary changes are not always evident from a
classic spirometry exam. In these conditions, FeNO pro-
vides an added value in the early diagnosis of an active
inflammatory process [90]. FeNO has already been accepted
in literature as an indirect marker of airway inflammation
used to monitor/manage asthma and prevent its recurrences
[91]. Measurement of FeNO has also been suggested as
a biomarker of several nonpulmonary diseases (Table 1).
Different theories have been suggested to explain why FeNO
measurement should be increased in nonpulmonary diseases:
(1) leukocyte priming and subsequent homing in embryoni-
cally related tissues (as between lung and bowel) [92, 93] and
(2) proinflammatory cytokine release from lesioned tissue
driven by blood to the lung [19]. An increasing body of
evidence has claimed the clinical usefulness of this method in
daily practice as well as in nonrespiratory diseases. Decreased
FeNO in heart disease may suggest a failure in compensatory
circulatory mechanisms, as found in congestive heart failure
(CHF) [93] and pulmonary hypertension (PH). Low alveolar
NO is considered a marker of hypoxia and endothelial
dysfunction since hypoxia induces vasoconstriction [85].The
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same explanatory mechanism is also described in obstructive
sleep apnea syndrome (OSAS) where the alveolar component
(CANO) is decreased [94], most likely subsequent to hypoxia
[95]. Although CANO is decreased in OSAS, overall FeNO
is increased because the main component is produced by
the upper airways [96]. Conversely, increased FeNO levels
might reflect excessive vasodilation as in hepatopulmonary
syndrome (HPS) [97] or be the consequence of a systemic
high level of inflammatory cytokines as in Hodgkin’s Lym-
phoma (HL) [98], systemic sclerosis (SSc) [99], Crohn’s
disease (CD) [91], and other inflammatory bowel diseases
(IBDs) [92]. Perturbation of metabolism, such as in obesity,
that leads to a proinflammatory condition may elevate FeNO
as demonstrated by the correlation between body mass index
(BMI) and FeNO [47].
6. Psoriasis and Nitric Oxide Production
The skin of psoriatic patients, both lesional and nonlesional,
globally presents increased proinflammatory cytokine pat-
terns, characterized by the presence of IFN𝛾, TNF𝛼, IL-8, IL-1
and IL-6, and IL-17 [100–102]. NO is a labile mediator and can
be detected at high levels in psoriatic plaques in the presence
of these cytokines which results in overtranscription of iNOS
and arginase through NF𝜅B signaling [103]. Although at
low concentrations NO is physiologically and continuously
released by the respiratory epithelium and endothelium [28],
to enable high concentrations of NO release a stimulus is
needed [104, 105]. Psoriasis causes endothelial vessel dysfunc-
tion [104] and an accumulation of asymmetrical dimethyl
arginine (ADMA), NOS inhibitors [106], and decreased free
NOcontent in blood [107]. At the same time, blood transports
the locally produced proinflammatory cytokines that trigger
inflammation in distant tissues. The production of NO is
increased in many skin diseases such as contact dermatitis,
atopic dermatitis, and psoriasis [108–111].The increased levels
of NO suggest a role for this molecule in maintaining
the proinflammatory microenvironment of psoriasis. NO
is described as capable of initiating psoriasis mainly by
releasing calcitonin gene-related peptide and substance P.
These substances are considered to play important roles
in the pathogenesis of psoriasis by inducing the produc-
tion of adhesion molecules, keratinocyte hyperproliferation,
mast cell degranulation, vasodilatation, and chemotaxis of
neutrophils [112]. NO stimulates epithelial cells to release
chemokines and growth factors which appear to be important
for keratinocyte proliferation and angiogenesis [113]. In
psoriatic lesions, an overexpression of iNOS is associated
with a compensatory increase of arginase-1 enzyme which
may reduce the NO availability [114–120]. On the other
hand, direct measurements of NO production in psoriatic
lesions did not show any evidence of competitive inhibition
[117]. In psoriasis patients, serum NO levels correlated with
the Psoriasis Area Severity Index (PASI) [121] highlighting
an important relationship between active disease and an
increased level of FeNO [19]. Recently, a positive correlation
between the PASI score and FeNO values has also been
found at a flow of 50 mL s−1, which would reveal the
presence of subclinical respiratory inflammation in patients
with psoriasis [19]. Persistent inflammation may produce a
change in airway microstructure, decreasing dynamicity and
functionality [122]. Microstructure change may reflect a loss
of function and a risk of developing respiratory disease. A
demonstration of chronic subclinical inflammation could be
useful in identifying the underlying biological mechanism
contributing to the aetiology of chronically compromised
respiratory function such as COPD [122] or OSAS [10].
It is noteworthy that psoriasis, COPD, and OSAS present
some common risk factors such as obesity, smoking, physical
inactivity, and metabolic syndrome. The vast majority of
current studies are not prospective which prevents a clear
establishment of a causal relationship.
7. Conclusion
Measurement of FeNO is an easy to perform, noninvasive,
reproducible test which requires relatively low collabora-
tion. The current available data seem to suggest that the
proinflammatory systemic status due to psoriasis [123] may
involve also the respiratory tract [124]. From this perspective,
FeNO should be a part of screening moderate-to-severe
psoriasis patients. The studies published to date encourage its
introduction in daily practice and its inclusion into research
of new biomarkers [19, 125]. Further studies are needed to
validate existing data on FeNO measurement and to firmly
establish it as part of standard screening in patients with
moderate-to-severe psoriasis.
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